Breaks Categories: News

FridayNov 15, 2024 2:15 pm

BioMedNewsBreaks — Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG) Marks Tremendous Milestone with $50M Public Offering

Alpha Cognition (NASDAQ: ACOG) (CSE: ACOG), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, recently announced the pricing of its upsized public offering of 8,695,653 common shares, each at a public offering price of $5.75, for gross proceeds of approximately $50 million. In addition, the company granted the underwriters a 30-day option to purchase up to an additional 1,184,592 common shares to cover over-allotments at the public offering price, less the underwriting discount. Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for the offering. “This offering serves as a tremendous…

Continue Reading

FridayNov 15, 2024 9:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast Track and Orphan Drug Designations from the FDA. The company also licensed TPI 287, a late-stage candidate for brain malignancies, with plans for FDA engagement on future studies. CNS ended the quarter with $7.0 million in cash and additional funding, ensuring operations through Q2 2025.…

Continue Reading

FridayNov 15, 2024 9:10 am

BioMedNewsBreaks – HealthLynked Corp. Restructures for Growth, Reports Declines in Revenue and Increased Losses in Q3 2024

HealthLynked (OTCQB: HLYK) has announced its Q3 2024 financial results, reflecting a strategic shift toward software solutions and a leaner operational model. Revenue dropped 56% year-over-year to $0.59 million, attributed to disruptions from clinical restructuring efforts, while operating expenses fell 10% in Q3 and 19% year-to-date due to efficiency initiatives. However, the company reported a $1.97 million net loss for the quarter, primarily due to the absence of a one-time $1.08 million gain recorded in 2023. HealthLynked is pivoting away from traditional clinical operations, focusing on app-based services to expand its user base and enhance operational scalability. To view the…

Continue Reading

ThursdayNov 14, 2024 8:00 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Reports Q3 Financials, Highlights Growth from Progressive Care and Outfitter Satellite Acquisitions

NextPlat (NASDAQ: NXPL, NXPLW)  reported Q3 2024 results reflecting the impact of its recent acquisitions, including Progressive Care and Outfitter Satellite, which contributed to consolidated revenues of $15.4 million. While healthcare revenue declined due to lower prescription reimbursement rates, e-Commerce revenue saw a 31% increase, largely from the Outfitter acquisition. The company recorded a net loss of $4.2 million due to increased expenses, including a non-cash impairment of Progressive Care’s intangible assets. Recent developments include expanding healthcare contracts and satellite communication device sales, along with a strengthened e-commerce presence in China and the UK. NextPlat projects ongoing growth from integration…

Continue Reading

WednesdayNov 13, 2024 2:28 pm

BioMedNewsBreaks — Astiva Health Earns Prestigious 4-Star CMS Rating

Astiva Health, a fast-growing leader in culturally responsive Medicare Advantage Prescription Drug (“MAPD”) health plans, today announced that it has earned a 4-star rating from the Centers for Medicare & Medicaid Services (“CMS”) for 2025. The CMS rating system evaluates Medicare Advantage (“Part C”) and Prescription Drug (“Part D”) plans on more than 40 quality and performance measures. The notable achievement highlights Astiva Health’s commitment to delivering high-quality, personalized healthcare, particularly to underserved populations across Southern California. "We are very proud to have earned this 4-star rating from CMS in just our first few years of operation," said Dr. Tri…

Continue Reading

WednesdayNov 13, 2024 12:35 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Unveils New Suite of Next-Gen Nutritional Products

BioAdaptives (OTC: BDPT), a leading provider of innovative nutritional products, today announced a transformative shift in its product lineup, replacing its entire portfolio of legacy products with a new suite of scientifically advanced solutions. The strategic move aims to deliver enhanced customer value, aligning each new offering directly with identified market needs through a rigorous product-market-fit approach. The redesigned lineup includes nutritional products for weight management, wellness, muscle and tissue repair, anti-aging for humans and Paw Partners, each developed with advanced scientific research and tailored to address specific pain points in the marketplace. “We are excited to introduce our new…

Continue Reading

WednesdayNov 13, 2024 10:17 am

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway

Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for accelerated approval of CNM-Au8 for ALS, a 1-for-20 reverse stock split to meet Nasdaq requirements, an amended debt facility extending funding into Q2 2025, and a $7.3 million funding round. Clene’s Phase 3 RESTORE-ALS trial was presented in October, showcasing the company's commitment to ALS treatment innovation. Financially, Clene ended Q3 with $14.6 million in cash and reported an $8.0 million net loss, reflecting decreased R&D and G&A expenses, but lower gains…

Continue Reading

TuesdayNov 12, 2024 8:20 am

BioMedNewsBreaks – Annovis Bio Inc. CEO to Showcase Buntanetap’s Dual Benefits for Alzheimer’s and Parkinson’s at NIA Workshop

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer’s and Parkinson’s Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment. To view the full press release, visit https://ibn.fm/pOQ1C About…

Continue Reading

MondayNov 11, 2024 9:58 am

BioMedNewsBreaks — Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing

Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened…

Continue Reading

MondayNov 11, 2024 8:30 am

BioMedNewsBreaks – HealthLynked Corp. Enhances Oohvie App with Telemedicine and Online Scheduling

HealthLynked (OTCQB: HLYK) has announced a significant update to its Oohvie app, integrating telemedicine services and online scheduling to offer a more comprehensive healthcare experience for women. The update includes a redesigned home screen, enhanced user interface, and expanded functionalities, enabling users to manage their health more effectively through a single platform. CEO Dr. Michael Dent stated that the alignment of Oohvie’s features with the HealthLynked network simplifies personalized, connected care by providing access to telemedicine, appointment scheduling, and secure health data management in one place. To view the full press release, visit https://ibn.fm/C4jIm About HealthLynked Corp. HealthLynked Corp. is committed to…

Continue Reading